Antifibrotic treatment prevalence, clinical outcomes, and economic burden among veterans with idiopathic pulmonary fibrosis in the United States

Reduction in hospitalizations following initiation of amikacin liposome inhalation suspension: A retrospective cohort study of patients in real-world settings

by | May 23, 2022 | Presentations, Pulmonary posters, Rare Diseases Posters

Abstract RATIONALE Mycobacterium avium complex (MAC) lung disease (LD) is a rare infectious disease with substantial disease burden, high rates of hospitalizations, and where 20% to 40% of patients do not respond to prescribed treatments. In 2018, amikacin liposome...
Antifibrotic treatment prevalence, clinical outcomes, and economic burden among veterans with idiopathic pulmonary fibrosis in the United States

The effectiveness of selexipag in pulmonary arterial hypertension patients with and without associated connective tissue disease comorbidity in United States

by | May 23, 2022 | Cardiovascular Posters, Presentations, Pulmonary posters

Abstract RATIONALE: Patients diagnosed with pulmonary arterial hypertension (PAH) and connective tissue disorders (CTD) have a poorer prognosis than those diagnosed with PAH not associated with CTD. In the pivotal GRIPHON study, the efficacy and safety of selexipag in...